Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S4W-02868 · Session 4

What assessment it has made of the (a) clinical and (b) social cost of not providing transcatheter aortic valve implantation treatment.

Answered Asked by Jackie Baillie Lab Lodged 21 Sep 2011

The question

To ask the Scottish Executive what assessment it has made of the (a) clinical and (b) social cost of not providing transcatheter aortic valve implantation treatment.

The answer

Answered by Nicola Sturgeon on 5 Oct 2011 · 14 days after it was lodged, on time

The Scottish Government’s Quality Strategy commits us to ensure that healthcare services are not only person-centred, but also effective and safe. As such, the introduction of any new health technology should be guided by those principles.
An assessment of the clinical and cost effectiveness of transcatheter aortic valve implantation (TAVI) and its safety, was a central part of the National Planning Forum’s (NPF) original review of TAVI in February 2011.
The NPF concluded that there was insufficient evidence at that point in time, to support a recommendation that a TAVI service should be established in Scotland, on the basis that the long term outcomes are unknown, there is only limited evidence of clinical efficacy and no evidence of cost effectiveness. This conclusion is supported by the most recent findings of the Scottish Health Technologies Group.
The National Institute for Health Research has also commissioned a Health Technology Assessment (HTA) looking at cost effectiveness. Publication of this HTA in December will trigger a further review by the Scottish Health Technologies Group.
As agreed at the time of the original review of TAVI in February 2011, NHSScotland will take this emerging evidence into account in its future consideration of the provision of TAVI by the end of February 2012.
Meantime, we expect that NHS boards should continue to ensure that local arrangements are in place so that people with severe aortic stenosis get access to appropriate clinical treatment. As part of those arrangements, where it is considered clinically appropriate by their doctors, patients can get access to TAVI treatment through consideration by an individual case panel.

In the Official Report

No contribution in the Official Report cites S4W-02868 by reference.